Prodisc-C Vivo implants are intended as cervical disc replacements and serve to restore disc height and maintain segmental movement.
What is the clinical problem?
Vertebral fusion is usually the standard therapy for the surgical treatment of herniated discs or degenerative complaints in the cervical spine. This procedure is successful in many patients, but leads to a loss of mobility and flexibility in the treated segment.
The Prodisc C Vivo maintains mobility between the vertebrae and in the treated segment. In addition, the adjacent segments are subjected to a deeper load such as after stiffening.
How does Prodisc C Vivo work?
The Prodisc C Vivo consists of a cranial and a caudal implant-endplate. The inlay is made of ultra-high molecular polyethylene. The ball and socket joint principle allows a physiological range of motion with regard to flexion/extension, rotation and lateral bending.
The prosthesis is implanted by a standard anterior access of the cervical spine. After removal of the disc, the size is determined by the trial implants. The aim is to select the best possible anatomical fit, i.e. an implant with the largest contact surface and the smallest height, in order to replace the natural intervertebral disc optimally.
Under image intensifier control, the implant is inserted by slight hammering.
Results Prodisc C
The Prodisc C prosthesis is the most documented disc prosthesis on the market. The studies show a high level of patient satisfaction.
- Chang UK, Kim DH, Lee MC, Willenberg R, Kim SH, Lim J. Range of motion change after cervical arthroplasty with ProDisc-C and Prestige artificial discs compared with anterior cervical discectomy and fusion. J Neurosurg Spine.2007 Jul;7(1):40-6.
- Singh K, Phillips FM, Park DK, Pelton MA, An HS, Goldberg EJ. Factors affecting reoperations after anterior cervical discectomy and fusion within and outside of a Federal Drug Administration investigational device exemption cervical disc replacement trial. Spine J. 2012 May;12(5):372-8.
- Upadhyaya CD, Wu JC, Trost G, et al. Analysis of the three United States Food and Drug Administration investigational device exemption cervical arthroplasty trials. J Neurosurg Spine. 2012;16(3):216–228.